EMA Authorised: Fingolimod Mylan (Fingolimod) — Mylan Pharmaceuticals Limited

View source ↗

Summary

The European Medicines Agency authorised Fingolimod Mylan, a generic version of fingolimod, for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod Mylan (Fingolimod)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Mylan Pharmaceuticals Limited. Decision date: 06/11/2025